Answers are grounded in this paper and cite their sources.
Meta-analysis identifies risk factors for positive pathology in non-muscle invasive bladder cancer after re-TUR, suggesting implications for treatment strategy.
To systematically evaluate the risk factors associated with positive pathology results following second transurethral resection (re-TUR) in patients with non-muscle invasive bladder cancer (NMIBC), a thorough database search, including PubMed, Embase, Cochrane Library, and CNKI, was performed, limited to studies published up to January 2023. Researchers independently conducted literature screening, data extraction, and meta-analysis using RevMan 5.3, incorporating 15 studies with 1,877 patients. Based on the results, positive pathology results after re-TUR were associated with the following factors: higher pathological grade (OR = -0.24, 95% CI: -0.31-0.17; p <0.001), tumour size ≥3 cm (OR = 0.40, 95% CI: 0.22-0.72; p = 0.003), multiple tumours (OR = 0.47, 95% CI: 0.37-0.61, p <0.001), absence of muscularis propria in the initial resection specimen (OR = 0.19, 95% CI: 0.09-0.39; p <0.001), concurrent carcinoma in situ (CIS, OR = 2.99, 95% CI: 1.52-5.87; p = 0.002), a history of bladder cancer recurrence (OR = 2.32, 95% CI: 1.30-4.13; p = 0.004), and treatment at different medical institutions for the first and second resections (OR = 0.23, 95% CI: 0.12-0.45; p <0.001). This study indicates that higher pathological grade, tumour size ≥3 cm, multiple tumours, the absence of muscularis propria in the initial resection specimen, and concurrent CIS are risk factors for positive pathology results after re-TUR in NMIBC patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: